Spire Inc. will hold a conference call and webcast on November 17, 2026, to discuss its fiscal 2026 fourth quarter and year-end financial results, along with earnings guidance and other updates. A news release will be issued before the market opens that day. The call will be accessible via phone and webcast, with a replay available until November 24. Spire is a major natural gas provider serving nearly 2 million customers in several U.S. states, focusing on growth and infrastructure investment.
Spire's upcoming fiscal 2026 year-end earnings call is noted here alongside current Utilities-sector data from Pluang as of Oct 20, 2026 03:02 WIB. Among 40 priced US Utilities stocks, 12 rose and 28 fell today. Notably, CEG traded at USD 263.37 with a 1-day decline of 2.95% and a nearly balanced Pluang order activity of 52% Sell to 48% Buy, contrasting with OKLO at USD 27.25 which saw a 2.57% drop and a heavier sell bias of 70% Sell to 30% Buy. NGG was priced at USD 79.14, down 2.56%. Typical hold times on Pluang ranged from 34 to 43 days for these assets.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
